Published in Exp Biol Med (Maywood) on June 01, 2013
Opioid growth factor and the treatment of human pancreatic cancer: a review. World J Gastroenterol (2014) 0.81
Inhibition of the growth of human melanoma cells by methionine enkephalin. Mol Med Rep (2016) 0.75
Developmental Toxicity of Zinc Oxide Nanoparticles to Zebrafish (Danio rerio): A Transcriptomic Analysis. PLoS One (2016) 0.75
The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev (2002) 1.71
Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Exp Biol Med (Maywood) (2011) 1.47
Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med (Maywood) (2011) 1.44
Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer. Exp Biol Med (Maywood) (2012) 1.39
Regulation of cell proliferation by the opioid growth factor receptor is dependent on karyopherin beta and Ran for nucleocytoplasmic trafficking. Exp Biol Med (Maywood) (2010) 1.38
The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Mol Biol Cell (2008) 1.25
Naltrexone, an opioid antagonist, facilitates reepithelialization of the cornea in diabetic rat. Diabetes (2002) 1.10
Use of topical insulin to normalize corneal epithelial healing in diabetes mellitus. Arch Ophthalmol (2007) 1.01
Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. Am J Physiol Regul Integr Comp Physiol (2009) 0.98
Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis. Brain Res (2009) 0.97
The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer. Cancer Res (2007) 0.96
Topically applied naltrexone restores corneal reepithelialization in diabetic rats. J Ocul Pharmacol Ther (2007) 0.95
Insulin treatment ameliorates impaired corneal reepithelialization in diabetic rats. Diabetes (2006) 0.94
Opioids and the apoptotic pathway in human cancer cells. Neuropeptides (2003) 0.93
Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Exp Biol Med (Maywood) (2008) 0.93
Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. Cancer Chemother Pharmacol (2005) 0.93
Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis. Am J Physiol Regul Integr Comp Physiol (2009) 0.92
Immunoelectron microscopic localization of the opioid growth factor receptor (OGFr) and OGF in the cornea. Brain Res (2003) 0.91
Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium. Anat Rec A Discov Mol Cell Evol Biol (2005) 0.91
Treatment of advanced pancreatic cancer with opioid growth factor: phase I. Anticancer Drugs (2004) 0.90
Opioids and differentiation in human cancer cells. Neuropeptides (2005) 0.90
The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol Cancer (2008) 0.89
Naltrexone accelerates healing without compromise of adhesion complexes in normal and diabetic corneal epithelium. Brain Res Bull (2007) 0.89
Dry eye reversal and corneal sensation restoration with topical naltrexone in diabetes mellitus. Arch Ophthalmol (2009) 0.88
Differential effects of vascular growth factors on arterial and venous angiogenesis. J Vasc Surg (2002) 0.88
Naltrexone and insulin are independently effective but not additive in accelerating corneal epithelial healing in type I diabetic rats. Exp Eye Res (2009) 0.87
Dependence on nuclear localization signals of the opioid growth factor receptor in the regulation of cell proliferation. Exp Biol Med (Maywood) (2009) 0.86
B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases. Immunobiology (2010) 0.86
Topical application of naltrexone facilitates reepithelialization of the cornea in diabetic rabbits. Brain Res Bull (2009) 0.85
Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor. Int J Oncol (2008) 0.84
Opioids and migration, chemotaxis, invasion, and adhesion of human cancer cells. Neuropeptides (2007) 0.84
Corneal safety of topically applied naltrexone. J Ocul Pharmacol Ther (2006) 0.84
Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol (2005) 0.83
Particle-mediated gene transfer of opioid growth factor receptor cDNA regulates cell proliferation of the corneal epithelium. Cornea (2005) 0.83
Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells. Int J Oncol (2007) 0.83
Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established experimental autoimmune encephalomyelitis. Brain Res (2012) 0.83
The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer. Am J Physiol Regul Integr Comp Physiol (2009) 0.82
The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Gynecol Oncol (2011) 0.82
Passive diffusion of naltrexone into human and animal cells and upregulation of cell proliferation. Am J Physiol Regul Integr Comp Physiol (2009) 0.82
Adaptation of homeostatic ocular surface epithelium to chronic treatment with the opioid antagonist naltrexone. Cornea (2006) 0.82
Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells. Int J Oncol (2004) 0.82
The expression and function of the OGF-OGFr axis - a tonically active negative regulator of growth - in COS cells. Neuropeptides (2003) 0.81
Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis. Exp Biol Med (Maywood) (2009) 0.81
Regulation of corneal repair by particle-mediated gene transfer of opioid growth factor receptor complementary DNA. Arch Ophthalmol (2006) 0.80
T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases. Immunobiology (2010) 0.80
Regulation of Tenon's capsule fibroblast cell proliferation by the opioid growth factor and the opioid growth factor receptor axis. Invest Ophthalmol Vis Sci (2010) 0.80
Targeting opioidergic pathways as a novel biological treatment for advanced pancreatic cancer. Expert Rev Gastroenterol Hepatol (2012) 0.79
Treatment of a relapse-remitting model of multiple sclerosis with opioid growth factor. Brain Res Bull (2013) 0.79
Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers. Int J Oncol (2006) 0.79
Ocular surface abnormalities related to type 2 diabetes are reversed by the opioid antagonist naltrexone. Clin Experiment Ophthalmol (2013) 0.79
Opioid growth factor inhibits intimal hyperplasia in balloon-injured rat carotid artery. J Vasc Surg (2003) 0.79
Expression of opioid growth factor (OGF)-OGF receptor (OGFr) axis in human nonmedullary thyroid cancer. Thyroid (2008) 0.79
Topical treatment with the opioid antagonist naltrexone accelerates the remodeling phase of full-thickness wound healing in type 1 diabetic rats. Exp Biol Med (Maywood) (2013) 0.79
Opioid growth factor modulation of corneal epithelium: uppers and downers. Curr Eye Res (2003) 0.78
Prevention of exuberant granulation tissue and neovascularization in the rat cornea by naltrexone. Arch Ophthalmol (2008) 0.78
Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment. Invest New Drugs (2012) 0.77
Gene expression of OGFr in the developing and adult rat brain and cerebellum. Brain Res Bull (2004) 0.77
Internalization of the opioid growth factor, [Met5]-enkephalin, is dependent on clathrin-mediated endocytosis for downregulation of cell proliferation. Am J Physiol Regul Integr Comp Physiol (2010) 0.77
Low Dose Naltrexone for Treatment of Multiple Sclerosis: A Retrospective Chart Review of Safety and Tolerability. J Clin Psychopharmacol (2015) 0.77
Astrocyte proliferation is regulated by the OGF-OGFr axis in vitro and in experimental autoimmune encephalomyelitis. Brain Res Bull (2012) 0.77
Expression of the opioid growth factor-opioid growth factor receptor axis in human ovarian cancer. Gynecol Oncol (2011) 0.76
Spontaneous episodic decreased tear secretion in rats is related to opioidergic signaling pathways. Invest Ophthalmol Vis Sci (2012) 0.76
Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer. Exp Biol Med (Maywood) (2013) 0.76
Targeting opioid signaling in Crohn's disease: new therapeutic pathways. Expert Rev Gastroenterol Hepatol (2011) 0.75